NCT Number: NCT07023224
The aim of this methodological study was to investigate the Turkish validity and reliability of the Parkinson's Disease Dyskinesia Scale (PDYS-26).The scale evaluates choreic dyskinesia.Measures the impact of dyskinesia on activities of daily living in patients with Parkinson's disease.
Hypotheses of the Study:
* Parkinson's Disease Dyskinesia Scale (PDYS-26) is reliable in Turkish. * Parkinson's Disease Dyskinesia Scale (PDYS-26) is valid in Turkish.
To determine the validity of dyskinesia;
* Tampa Kinesiophobia Scale, * Mini BesTest, * Activity Specific Balance Safety Scale (ABC) and * Parkinson's Disease Questionnaire-39 will be evaluated.
Interested in participating?
Request InfoAll sexes
Observational
Bakirçay University Çiğli Regional Education Hospital, Izmir, İ̇zmi̇r, Turkey (Türkiye)
In Parkinson's disease, a neurodegenerative disorder affecting the peripheral and central nervous system, dyskinesia is a common symptom that occurs as disease processes progress and leads to disability. The term dyskinesia is a general term that covers many movement disorders. In general, it can be defined as mild to severe abnormal and involuntary muscle movements. In individuals with Parkinson's disease, it is a natural consequence of the neurodegenerative process and a motor complication of the gold standard L-dopa. Assessment of dyskinesia in Parkinson's patients is important for the implementation of appropriate medical, surgical and rehabilitation protocols. There are few scales and patient diaries that clinically assess the effect of interventions for dyskinesia. At the same time, there are deficiencies related to the reliability and validity studies of these existing scales in different languages. Therefore, limitations may arise in the assessment of dyskinesia. For this purpose, our study aims to investigate the reliability and validity of the Parkinson's Disease Dyskinesia Scale (PDYS-26) in Turkish in patients diagnosed with 130 idiopathic Parkinson's patients.In the study, the Parkinson's Disease Dyskinesia Scale (PDYS-26) will be translated into Turkish with the "back translation" method and will be finalized after the approval of the commission consisting of relevant health professionals. The final version of the scale will be applied to Parkinson's patients. To determine the validity of dyskinesia; Tampa Kinesiophobia Scale, Mini BesTest Activity Specific Balance Safety Scale (ABC) and Parkinson's Disease Questionnaire-39 will be evaluated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Turkish adaptation of the Parkinson's Disease Dyskinesia Scale (PDYS-26) is administered to individuals diagnosed with Parkinson's disease who have a dyskinesia score of ≥1 based on the Unified Parkinson's Disease Rating Scale (UPDRS) dyskinesia item. The scale is used to evaluate dyskinesia severity and assess its clinical applicability in Turkish-speaking populations.
Time frame: Baseline (Day 1) and 7 days post-baseline (Day 8)
Turkish version of Parkinson's Disease Dyskinesia Scale: It is a questionnaire that assesses the impact of dyskinesia on activities of daily living. It consists of 26 items. A higher score indicates greater impact.It is considered a consistent, reliable, and valid measure. It is easy to complete and has a short administration time.
Time frame: Baseline (Day 1)
Tampa Kinesiophobia Scale: It consists of 17 items that assess avoidance of movement due to a history of injury or pain.
The minimum score is 17 and the maximum score is 68; a score of 37 or above indicates a high level of kinesiophobia.
A 4-point Likert scale is used to evaluate the responses (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree).
Time frame: Baseline (Day 1)
Mini BesTest Balance Scale: It is one of the clinical tests used to assess gait and balance. It consists of 4 subcomponents: anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait, with a total of 14 items. A higher score indicates better function.
Time frame: Baseline (Day 1)
Activity Specific Balance Safety Scale: It evaluates the individual's perceived level of confidence during balance-related activities of daily living.
The level of confidence is assessed by the evaluator through 16 items directly asked to the individual, with scores ranging from 0% (no confidence) to 100% (complete confidence).
A total score between 0 and 49 indicates a low functional level, 50 to 80 indicates a moderate functional level, and 81 to 100 indicates a high functional level.
Time frame: Baseline (Day 1)
Parkinson's Disease Questionnaire-39: It is one of the most commonly used scales for assessing quality of life in individuals with Parkinson's disease.
It evaluates the impact of Parkinson's disease on quality of life over the past month. Lower total scores indicate better quality of life.
Contact information is provided by the study sponsor or research team.
Izmir Bakircay University
Other
Adaptation Of The Parkinson's Disease Dyskinesia Questionnaire Into Turkish And Its Validity And Reliability In Parkinson's Patient
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06680830
Basal Ganglia Diseases, Brain Diseases
Sun City, Arizona, United States
View Trial DetailsNCT06556173
Basal Ganglia Diseases, Brain Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT02445651
Basal Ganglia Diseases, Brain Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07163156
Basal Ganglia Diseases, Brain Diseases
Çanakkale, Merkez, Turkey (Türkiye)
View Trial Details